Background and Objectives Antiretrovirals are currently used for the treatment and prevention of HIV infection. However, poor adherence and low tolerability of some existing oral formulations can hinder their efficacy. Longacting (LA) injectable nanoformulations could help address these complications by simplifying antiretroviral administration. The aim of this study is to inform the optimisation of intramuscular LA formulations for eight antiretrovirals through physiologically based pharmacokinetic (PBPK) modelling. Methods A whole-body PBPK model was constructed using mathematical descriptions of molecular, physiological and anatomical processes defining pharmacokinetics. These models were validated against available clinical data and subsequently used to predict the pharmacokinetics of injectable LA formulations Results The predictions suggest that monthly intramuscular injections are possible for dolutegravir, efavirenz, emtricitabine, raltegravir, rilpivirine and tenofovir provided that technological challenges to control their release rate can be addressed. Conclusions These data may help inform the target product profiles for LA antiretroviral reformulation strategies.
obtained through the use of two or more antiretroviral [2] classes in combination. Antiretrovirals can also be used for pre-exposure prophylaxis (PrEP) strategies, preventing the transmission of HIV to uninfected individuals who are at high risk of acquiring the infection [3] .
Currently available oral formulations necessitate lifelong daily dosing and subjects often encounter pill fatigue as a consequence. This has the potential of producing suboptimal adherence, which has emerged as one of the main causes of therapeutic failure and low rates of PrEP protection [4] . The introduction of long-acting (LA) formulations could revolutionise treatment and PrEP by enabling administration once monthly or even less frequently. This can simplify antiretroviral administration and improve adherence [5] . LA formulations are most commonly administered parenterally, decreasing inter-and intra-patient variability in drug exposure. Additional potential advantages include a decrease in overall drug consumption and cost of treatment [6] . LA injectable contraceptives and antipsychotics are widely used and have excellent efficacy and tolerability compared with oral routes of administration [4] .
Recently, injectable LA formulations of the antiretrovirals rilpivirine and S/GSK1265744 (cabotegravir) have been developed with the potential for once-monthly, or less frequent, dosing [4] . The development of the first injectable LA antiretroviral formulations has led to considerable interest amongst patients; a recent study found that 84 % of surveyed patients would definitely or probably try a oncemonthly injectable LA antiretroviral [7] . The LA formulations are based on solid drug nanoparticles (SDNs) which release the drug from the depot over a protracted period of time. The optimisation of SDNs for LA administration is complicated by several pharmacokinetic factors and has to take into account the optimal dose and drug release into the circulation to achieve therapeutic or prophylactic plasma concentrations for the entire dosing interval.
The pharmacokinetics of a drug are determined by processes that can be simulated through physiologically based pharmacokinetic (PBPK) models. PBPK models are based on the mathematical description of anatomical, physiological and molecular processes defining drug distribution, integrating information on drug characteristics and patient-specific factors [8] . This modelling approach can be applied to the development and optimisation of novel formulations to identify optimal pharmacokinetic characteristics [8] . PBPK models have been used extensively in different disease areas for the prediction of pharmacokinetics for novel drugs, optimisation of existing therapies and simulation of different clinical scenarios. Specifically, PBPK can be used to predict pharmacokinetics as a function of formulation and route of administration [9] . These predictions can then inform the design of LA formulations, identifying optimal characteristics in terms of dose and depot release rate. For antiretrovirals, this modelling approach has been applied to identify factors influencing the pharmacokinetics of novel formulations [10, 11] , the effect of genetics on drug distribution [11] , pharmacokinetics in special populations [12] and drug-drug interactions [13] .
The aim of this study was to simulate the pharmacokinetics of antiretrovirals after administration of virtual intramuscular LA formulations using PBPK modelling. The PBPK models were first validated against clinical data for oral counterparts, to assess the accuracy of the simulation. Theoretical target dose and release rate combinations for once-weekly and once-monthly intramuscular administration were then identified.
Methods
Virtual patients between the ages of 18 and 60 years were generated. All organs and tissues were represented as individual compartments. The model was based on the following assumptions: (1) well-stirred compartments with instant distribution of the drug; (2) no absorption of the drug from the colon; and (3) the model is blood flow limited. The PBPK model was designed using SimBiology Ò version 4.3.1, a product of MATLAB Ò version 8.2 (MathWorks, Natick, MA, USA 2013). The PBPK approach has been developed for key antiretrovirals [two nucleoside reverse-transcriptase inhibitors (NRTIs), tenofovir and emtricitabine; three non-NRTIs (NNRTIs), efavirenz, rilpivirine and etravirine; two integrase inhibitors, raltegravir and dolutegravir; and an unboosted protease inhibitor, atazanavir].
Anatomy
The age, body mass index, body surface area, height and weight of the individual were defined as previously described [14] . These initial values were used for the calculation of organ and tissue volumes through allometric equations [14] . The blood circulation was represented by considering the cardiac output and regional blood flows as previously described [14] .
Intestinal Absorption
A compartmental absorption and transit model was integrated to simulate for oral drugs as previously described [15] . The absorption rate was evaluated using the apparent permeability obtained from Caco-2 cells or the polar surface area and hydrogen bond donor (HBD) values as previously described [16] .
Intestinal Metabolism
The clearance of drugs in the gut (CL gut ) was calculated considering the in vitro intrinsic clearance (CL int ) and the abundance of cytochrome P450 (CYP) family 3, subfamily A-CYP3A in the intestinal tissue (Ab CYP3A ) (Eq. 1) [16, 17] :
CL gut ðL/h) = CL int Â Ab CYP3A Â 1; 000 Â 60 1; 000; 000 ð1Þ
The fraction of the drug transiting to the liver after metabolism in the gut (F g ) was computed using the following equation (Eq. 2):
where Q gut represents the blood flow to the gut and f u,gut is the fraction unbound in the gut.
First-Pass Metabolism
The total intrinsic clearance (TCL int ) of an enzyme was calculated as follows (Eq. 3): 
Then, the sum of the CL int values of all the enzymes that are metabolising the drug in the liver gives the total apparent clearance (CL app ) (Eq. 5):
The systemic clearance (CL) is calculated from the blood, and not the liver, and is given by Eq. 6:
where Q hv is the hepatic flow rate and f u is the fraction unbound in plasma. The fraction of the active drug that is available after first-pass hepatic metabolism (F h ) is given as follows (Eq. 7):
Systemic Distribution
The volume of distribution and systemic circulation was calculated using previously published equations [19, 20] .
Intramuscular Depot Compartment
A compartment was created to virtually represent the depot with a maximum volume of 6 mL since it is the maximum volume of injection that has previously been used for intramuscular administration, although lower volumes are usually needed for optimal tolerability [21] . The blood flow to this area was calculated accordingly. The release of the drug from the depot to the blood capillaries present in the muscle was given as follows (Eq. 8) [9] :
where A is the amount of drug released from the depot and k is the first-order release rate. A variability of ±10 % for the release rate values was considered.
The highest single dose that has been tested clinically is 1,500 mg with cefuroxime [21] . Therefore, any strategy for LA antiretroviral development needs to address depot volume and dose in order to successfully translate.
Model Validation
The physicochemical properties of antiretrovirals used to build the PBPK models are represented in Table 1 . The models were primarily validated against clinical data at steady state for oral formulations of the antiretrovirals ( Table 2 ). The model was also verified against an existing LA formulation of rilpivirine [6] .
Prediction of Pharmacokinetics Following Intramuscular Injection
In the prediction of intramuscular pharmacokinetics, the dose of the antiretroviral and release rate were optimised such that the mean trough concentration ( A dose cut-off of 1,500 mg was considered for intramuscular administration.
Prediction of Intracellular Concentrations
The active phosphate metabolite of tenofovir, tenofovir diphosphate (TFV-DP) intracellular concentrations were simulated as previously described [22] . The first-order elimination rate of emtricitabine triphosphate (FTC-TP) from the cellular compartment was calculated considering the elimination half-life of FTC-TP [23] . The maximum uptake velocity (V max ) and maximum velocity of anabolism (k m ) were fitted to obtain a zero-order dose input rate (k in )
such that the mean intracellular concentration of the active metabolite at steady state (C ss,avg ) was in accordance with available clinical data following Eq. 9:
where C is the concentration in the plasma. 
Values are expressed as arithmetic mean ± SD, mean (range), Geometric mean (% coefficient of variation) or mean for the presented data CL/F apparent oral clearance, CL int intrinsic clearance (lL/min/pmol), CYP cytochrome P450, F absolute bioavailability, HBD number of hydrogen bond donors, Ind 50 50 % induction expressed as lM, Ind max induction maximum expressed as lM, k a absorption coefficient, log P o:w partition coefficient between octanol and water, M2 second metabolite, P app drug permeability from apical to basolateral in Caco-2 cell monolayer, pKa logarithmic value of the dissociation constant, PSA polar surface area, R blood-to-plasma drug ratio, UGT uridine diphosphate glucuronosyltransferase, V d volume of distribution, -data not available a Value was an assumption (as the drug is similar to emtricitabine and tenofovir, value was not available in the literature) Values of 0.9 ± 0.18 ng 9 h/mL and 18 ± 3.6 ng/mL for V max and k m were suitable to obtain C ss,avg values comparable with previously published data for oral administration [23] . The optimisation of the dose and release rates for emtricitabine and tenofovir considered not only plasma concentrations but also the intracellular FTC-TP and TFV-DP over the reported in vitro 50 % inhibitory concentration (IC 50 ) values of 127 and 150 fmol/10 6 cells [24, 25] .
Results
The validation was conducted by comparing the mean simulated C trough , maximum plasma concentration (C max ) and area under the concentration-time curve (AUC) values with the available clinical data for oral administration and also for an existing LA intramuscular formulation of rilpivirine (600 mg; 100 mg/mL) (shown in Table 2 and Fig. 1 ). For emtricitabine and tenofovir, the C ss,avg of FTC-TP and TFV-DP were compared with clinical data [23] . Although the commonly agreeable limits of variability for validation is twofold from the mean value, we used a more stringent value of 0.5-fold to enhance the accuracy of the predictions [26] .
For intramuscular formulations, multiple-dose and release rate combinations were simulated to obtain mean predicted C trough values greater than the defined cut-off. For tenofovir and emtricitabine, the dose and release rates for intramuscular injection were optimised such that the plasma concentrations were over the IC 90 value and also the C ss,avg values were over the intracellular IC 50 .
A summary of the predicted AUC, C max and C trough values for eight antiretrovirals following optimal intramuscular injection is shown in Table 3 .
Rilpivirine
The validation of the PBPK model for rilpivirine was performed against available clinical data for the oral formulation. The simulated mean AUC, C max and C trough values deviated ?38.7, ?5.1 and ?6.5 %, respectively, from the clinical data [27] . The PBPK model was additionally validated against an existing LA intramuscular formulation of rilpivirine (600 mg; 100 mg/mL) [6] . The release rate from the intramuscular depot was predicted after matching the model to the clinical pharmacokinetic data. The drug release followed dose-dependent first-order kinetics and the release rate was predicted to be between 0.0009 and 0.0012 h -1 (Fig. 1) . The mean values for AUC were 84.0 vs. 83.38 ± 33.34 ng 9 h/mL, C max 96.7 vs. 86.73 ± 30.51 ng/mL and C trough 15.7 vs. 11.81 ± 6.3 ng/ mL for clinical versus simulated data. After the validation step with both oral and LA intramuscular formulations, the optimal dose and release rates of both weekly and monthly injection regimens of rilpivirine were identified such that the plasma concentration is over the PBIC 95 value of 20.3 ng/mL [28] . A weekly dose of 60 mg with a release rate of 0.015 h -1 and a monthly dose of 250 mg with a release rate of 0.002 h -1 were predicted to maintain the plasma concentrations above the target cut-off.
Atazanavir
The validation at steady state for the oral administration of unboosted atazanavir resulted in mean predicted AUC, C max and C trough values that were -16.9, -49.3 and ?50.0 % of those observed clinically [29] . An intramuscular dose of atazanavir 1,500 mg was predicted to result in plasma concentrations after 30 days below the PBIC 95 (60 ng/mL) and was therefore deemed unsuitable for monthly injection. An intramuscular weekly dose of 400 mg, however, was predicted to achieve mean [32] . Fig. 1 Validation of the physiologically based pharmacokinetic strategy against clinical data for an existing rilpivirine sustainedrelease formulation (600 mg; 100 mg/mL) [6] . S.D. standard deviation 
Emtricitabine
The predicted variation from the clinical values in mean AUC, C max and C trough for oral emtricitabine were -3.5, -34.0 and -28.1 %, respectively [33] , and the simulated mean C ss,avg of intracellular FTC-TP has a deviation of ?2.65 % from the clinical value (Table 4 ). The IC 90 value of 50.2 ng/mL and intracellular IC 50 of 127 fmol/10 6 cells were considered as target concentrations [23, 25] . The simulated intramuscular injection required a dose of 375 mg with a release rate of 0.009 h -1 for a weekly administration and 1,500 mg with a release rate of 0.0015 h -1 for a monthly administration [23] .
Efavirenz
The validated PBPK model yielded AUC, C max and C trough values that were ?13.7, -20.2 and -3.4 % compared with the clinical values [34] . In order to obtain plasma concentrations above the PBIC 95 value of 126 ng/mL, a weekly intramuscular dose of 200 mg (release rate -0.015 h -1 ) and monthly dose of 800 mg (release rate -0.007 h -1 ) were required [30] .
Etravirine
The validated PBPK model with oral administration of etravirine resulted in mean AUC, C max and C trough values that were ?6.1, -16.9 and ?21.0 % compared with the clinical values [35] . The intramuscular predictions indicate that etravirine may be suitable for weekly administration with a dose of 700 mg and release rate of 0.015 h , but not for monthly administration as the drug concentrations fall below the PBIC 95 value even for an intramuscular dose of 1,500 mg [30] .
Raltegravir
The predicted mean AUC, C max and C trough values of orally administered raltegravir were ?35.4, -20.5 and -23.1 % compared with the clinical values, respectively [36] . To maintain the plasma concentrations above the IC 95 value (15 ng/mL), the prediction suggested a dose of 200 mg (release rate -0.005 h -1 ) and 800 mg (release rate -0.002 h -1 ) may enable weekly and monthly intramuscular administration of raltegravir, respectively [37] .
Tenofovir Disoproxil Fumarate
The validated PBPK model for tenofovir disoproxil fumarate (TDF) predicted mean AUC, C max and C trough values that were ?41.6, ?78.0 and -67.9 % compared with the clinical data, respectively [38] . The deviation of the intracellular C ss,avg was ?3.85 % compared with the clinical value (Table 4) . TDF 200 mg with a release rate of 0.008 h -1 was predicted to provide a sufficient exposure following weekly intramuscular injection and TDF 1,300 mg with a release rate of 0.002 h -1 was an adequate dose for a monthly intramuscular administration, maintaining mean plasma concentrations above the IC 90 and intracellular TFV-DP above the IC 50 [24] .
Discussion
Imperfect adherence to daily oral antiretroviral formulations continues to hinder the efficacy of HIV therapy and PrEP. Alternative administration strategies are beginning to emerge that provide opportunities for once-monthly or even less frequent administration. A greater understanding of formulation characteristics is required to predict dose and release rates that provide adequate pharmacokinetic exposure relative to potency. This information will facilitate development of newer LA antiretroviral formulations.
In this study, PBPK modelling was used to predict the pharmacokinetics of antiretrovirals following intramuscular injection. The PBPK models were based on mathematical equations describing the human anatomy and physiology and the molecular processes regulating drug C max maximum concentration, C ss,avg mean steady-state concentration, C trough trough concentration at the end of the duration, IC 50 50 % inhibitory concentration release and distribution. The PBPK models were initially validated for eight orally administered antiretrovirals against available clinical data for oral formulations. Subsequently, intramuscular administration was simulated by adding an additional compartment to the model to represent the intramuscular depot. For this, a first-order kinetics constant was applied to represent the diffusion of antiretrovirals from the depot to the surrounding blood capillaries (as shown in Fig. 2 ). This approach was validated comparing simulated pharmacokinetics of rilpivirine following intramuscular injection versus available clinical data for the LA formulation. The primary objective of this study was to identify whether drug-specific doses and release rates from the depot predicted compatibility for intramuscular administration. To obtain the suppression of the viral replication, antiretroviral C trough should reach and be maintained at concentrations above the susceptibility of the virus to that drug. Where possible, dose and release rate were optimised such that the antiretroviral C trough remained above previously identified target values. Target concentrations were identified as equal to the PBIC 95 . Since emtricitabine and TDF are characterised by very low protein binding (\4 and \0.7 %, respectively) IC 90 values were considered (IC 95 data not available). The intracellular concentrations of FTC-TP and TFV-DP were also used as target concentrations in the optimisation of intramuscular dose and release rates for emtricitabine and tenofovir. Although the PBIC 95 represents a rational pharmacodynamic cut-off and has been discussed extensively elsewhere, some antiretrovirals do not exert a good relationship between C trough values and virologic efficacy [30] . In certain cases the clinical data indicate that the minimum effective concentrations for therapy might be considerably higher than the in vitro IC 95 . The validation of PBPK models is essential to identify the correct parameters for an accurate simulation of pharmacokinetics for each antiretroviral. Since dissolved molecules rather than nanoparticles are assumed to predominate systemically after intramuscular administration of SDNs, the volume of distribution, metabolism and elimination were fixed irrespective of the route of administration. As such, it should be noted that the presented data are only applicable when this is assumed to be the case, and these models cannot be applied to technologies that change Fig. 2 The whole-body physiologically based pharmacokinetic model with an additional compartment for intramuscular depot and the blood capillaries surrounding the depot. Each of the arrows represents the flow kinetics assumed between tissues in the model. The small intestine is divided into seven parts for effective absorption kinetics. Metabolism occurs in the liver and intestine. Unabsorbed drug is excreted through faeces and excretion occurs through the kidneys. The green line represents the kinetics of the release from the nanoparticulate intramuscular depot. IM intramuscular, LV left ventricle, RV right ventricle these parameters (e.g. nanocarrier systems such as nanoemulsions or polymeric nanoparticles). Each model prediction was carried out at steady state to better represent the long-term antiretroviral pharmacokinetics and relevant clinical scenarios. The model was considered validated if the mean AUC of the simulation for each antiretroviral was within ±50 % compared with clinically reported values.
The simulated values from all of the included PBPK models were in agreement with available clinical data and were therefore used for prediction of pharmacokinetics after intramuscular administration. The simulations were carried out for weekly and monthly administration and the maximum injectable dose was set to 1,500 mg since doses above this have not previously been practical for intramuscular formulations [21] . Table 3 illustrates that the release rate was inversely proportional to the dosage, and a slower release rate was required for monthly administration.
Our PBPK models predicted that two NRTIs, emtricitabine and tenofovir, may be suitable for weekly or monthly administration. Importantly, emtricitabine and tenofovir are widely used in HIV treatment and prevention, and LA formulations of these agents would make possible multidrug regimens that match current clinical paradigms for therapy. These agents also represent good candidates for monthly PrEP due to their excellent safety and efficacy profiles. Tenofovir alone or tenofovir combined with emtricitabine have already been shown to provide good protection against HIV infection in individuals at high risk of infection [3] .
Considering NNRTIs, efavirenz and rilpivirine were both predicted to be suitable for monthly administration. Both have long half-lives, which are favourable for development of LA agents. The high systemic clearance of etravirine limits the possibility of a monthly administration format when a dose limit of 1,500 mg is applied. Conversely, both integrase inhibitors, dolutegravir and raltegravir, were predicted to be suitable for monthly administration. A low dose of 105 mg was predicted to be sufficient for monthly administration of dolutegravir if a formulation with an optimised release rate can be developed. It should be noted that cabotegravir is chemically closely related to dolutegravir, and development of a dolutegravir LA formulation may therefore not be warranted. Our simulation indicated that raltegravir could potentially be developed as a monthly intramuscular injection with a dose of 800 mg. The optimised dose and release rate for unboosted atazanavir predicted feasibility of an injectable weekly option at 600 mg, but doses higher than 1,500 mg would be required for monthly administration.
The optimisation of LA strategies should be based on a rational analysis of several pharmacokinetic factors. For many agents, it is likely that the pharmacokinetic variability after intramuscular administration will be reduced compared to oral formulations, due to the lower complexity of the absorption process and avoidance of intestinal transporters and first-pass metabolism. Therapeutic plasma concentrations were predicted to be achieved in *8 h for emtricitabine and tenofovir and *24 h for the remaining antiretrovirals after a single intramuscular injection (as shown in Fig. 3 ). Since a day is needed to achieve therapeutic plasma concentrations for the other antiretrovirals, a loading oral dose equivalent to the daily regimen may be necessary. This could represent a minor risk for the development of drug resistance and therapeutic failure, but PBPK modelling may help to inform the ongoing debate regarding some aspects of the need for an oral lead-in with the same drugs. The co-administration of multiple injectable antiretrovirals is possible, but a rational selection of concomitant agents is needed to avoid drug-drug interactions. Studies to validate the utility of coadministration of the two existing LA drugs, rilpivirine and cabotegravir, are underway [39] .
The PBPK approach is characterised by some intrinsic limitations due to existing knowledge gaps and the complexity of biological processes underpinning drug distribution. For example, muscle tissues are well-connected to the lymphatic circulation, and drugs with high lipophilicity tend to diffuse through lymphatics rather than blood vessels [9] . Consequently, higher accumulation of antiretrovirals in lymph nodes might be possible, but there is a paucity of clinical data in this area for available LA formulations. Similarly, efflux and influx transporters are of clear importance to intestinal absorption, distribution and clearance of drugs, but there are currently very little data on whether these transporters (or metabolic enzymes) are expressed at the depot sites. Gender has been correlated with changes in plasma exposure in a recent clinical study of rilpivirine LA [40] . Although several suggestions have been put forward to explain this, the physiological and anatomical mechanisms characterising the gender differences have not been fully elucidated and consequently have not been included in our simulations.
Although the doses and release rates identified through these simulations set targets for optimal nanoparticle design, it is important to underscore that the technological challenges in achieving these formulation characteristics are not addressed in this work. Long-term stability of the antiretrovirals in the interstitial fluid present in the depot site is another important consideration. Since SDN strategies do not involve the use of a carrier with stable size and dissolution rates over time, the nanoparticle properties are likely to change over the dosing interval. Since this will alter the surface to mass ratio, an effect on antiretroviral release kinetics with downstream effect on the overall pharmacokinetics cannot be ruled out. It may also be important to consider other SDN components, such as polymers and surfactants, which will also be gradually released over time [41] . The use of LA injections of antiretrovirals might determine specific complications at the site of injection as described for other treatments; additionally, given the prolonged systemic exposition of LA antiretrovirals and the inability to interrupt the drug in the event of adverse effects, a period of oral induction might be considered before initiating LA injections. For patients discontinuing the LA antiretroviral therapy, an oral administration strategy should be considered in order to prevent resistance development due to the diminishing plasma concentrations [4] .
Conclusion
PBPK models for the simulation of pharmacokinetics after LA administration were successfully developed and validated against clinical data for eight approved antiretroviral drugs. The validated models were applied to identify theoretical optimal dose and release rates required to achieve therapeutic concentrations following intramuscular injection. This approach defines a new paradigm for the rational design of LA formulations incorporating pharmacological properties of candidate antiretrovirals. Antiretrovirals with potential for reformulation into intramuscular depots were identified, assuming the technological complexities associated with reformulation can be overcome. Based on their pharmacokinetic properties, dolutegravir, efavirenz, emtricitabine, raltegravir, tenofovir and rilpivirine are potential candidates for once-monthly injection. PBPK modelling represents an innovative pharmacological tool to inform drug and formulation design.
